218 related articles for article (PubMed ID: 34568834)
1. Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.
Romine KA; Nechiporuk T; Bottomly D; Jeng S; McWeeney SK; Kaempf A; Corces MR; Majeti R; Tyner JW
Blood Cancer Discov; 2021 Sep; 2(5):518-531. PubMed ID: 34568834
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
[TBL] [Abstract][Full Text] [Related]
3. Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia.
Monteith AJ; Ramsey HE; Silver AJ; Brown D; Greenwood D; Smith BN; Wise AD; Liu J; Olmstead SD; Watke J; Arrate MP; Gorska AE; Fuller L; Locasale JW; Stubbs MC; Rathmell JC; Savona MR
Cancer Res; 2024 Apr; 84(7):1101-1114. PubMed ID: 38285895
[TBL] [Abstract][Full Text] [Related]
4. Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors' Therapeutic Sensitivity in Acute Myeloid Leukemia.
Zha J; Lai Q; Deng M; Shi P; Zhao H; Chen Q; Wu H; Xu B
Stem Cell Rev Rep; 2020 Dec; 16(6):1280-1291. PubMed ID: 33057942
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response.
Conery AR; Centore RC; Spillane KL; Follmer NE; Bommi-Reddy A; Hatton C; Bryant BM; Greninger P; Amzallag A; Benes CH; Mertz JA; Sims RJ
Cancer Res; 2016 Mar; 76(6):1313-9. PubMed ID: 26759243
[TBL] [Abstract][Full Text] [Related]
6. The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR; Halpin M; Corbin DL; Asemelash Y; Sher S; Gordon BK; Whipp EC; Mitchell S; Harrington BK; Orwick S; Benrashid S; Goettl VM; Yildiz V; Mitchell AD; Cahn O; Mims AS; Larkin KTM; Long M; Blachly J; Woyach JA; Lapalombella R; Grieselhuber NR
Exp Hematol Oncol; 2024 Mar; 13(1):27. PubMed ID: 38438856
[TBL] [Abstract][Full Text] [Related]
7. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML).
Djamai H; Berrou J; Dupont M; Coudé MM; Delord M; Clappier E; Marceau-Renaut A; Kaci A; Raffoux E; Itzykson R; Berthier C; Wu HC; Hleihel R; Bazarbachi A; de Thé H; Baruchel A; Gardin C; Dombret H; Braun T
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829934
[TBL] [Abstract][Full Text] [Related]
8. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition.
Tambe M; Karjalainen E; Vähä-Koskela M; Bulanova D; Gjertsen BT; Kontro M; Porkka K; Heckman CA; Wennerberg K
Leukemia; 2020 Dec; 34(12):3186-3196. PubMed ID: 32651543
[TBL] [Abstract][Full Text] [Related]
9. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
Saenz DT; Fiskus W; Manshouri T; Rajapakshe K; Krieger S; Sun B; Mill CP; DiNardo C; Pemmaraju N; Kadia T; Parmar S; Sharma S; Coarfa C; Qiu P; Verstovsek S; Bhalla KN
Leukemia; 2017 Mar; 31(3):678-687. PubMed ID: 27677740
[TBL] [Abstract][Full Text] [Related]
10. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
[TBL] [Abstract][Full Text] [Related]
11. Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens.
Wright S; Hu J; Wang H; Hyle J; Zhang Y; Du G; Konopleva MY; Kornblau SM; Djekidel MN; Rosikiewicz W; Xu B; Lu R; Yang JJ; Li C
Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2220134120. PubMed ID: 37036970
[TBL] [Abstract][Full Text] [Related]
12. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
[TBL] [Abstract][Full Text] [Related]
13. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
14. Specific Activation
Li G; Zhang Z; Reszka-Blanco N; Li F; Chi L; Ma J; Jeffrey J; Cheng L; Su L
J Virol; 2019 Jun; 93(12):. PubMed ID: 30971469
[TBL] [Abstract][Full Text] [Related]
15. BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML.
Zhang S; Zhao Y; Heaster TM; Fischer MA; Stengel KR; Zhou X; Ramsey H; Zhou MM; Savona MR; Skala MC; Hiebert SW
J Cell Biochem; 2019 May; 120(5):7309-7322. PubMed ID: 30417424
[TBL] [Abstract][Full Text] [Related]
16. BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8
Romine KA; MacPherson K; Cho HJ; Kosaka Y; Flynn PA; Byrd KH; Coy JL; Newman MT; Pandita R; Loo CP; Scott J; Adey AC; Lind EF
Leukemia; 2023 Mar; 37(3):580-592. PubMed ID: 36681742
[TBL] [Abstract][Full Text] [Related]
17. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
18. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
Chen NC; Borthakur G; Pemmaraju N
Leuk Lymphoma; 2021 Mar; 62(3):528-537. PubMed ID: 33161793
[TBL] [Abstract][Full Text] [Related]
19. NR5A2 synergizes with NCOA3 to induce breast cancer resistance to BET inhibitor by upregulating NRF2 to attenuate ferroptosis.
Qiao J; Chen Y; Mi Y; Jin H; Huang T; Liu L; Gong L; Wang L; Wang Q; Zou Z
Biochem Biophys Res Commun; 2020 Sep; 530(2):402-409. PubMed ID: 32536370
[TBL] [Abstract][Full Text] [Related]
20. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
